Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
Tracon Pharmaceuticals, Inc. (TCON)
Sector: Healthcare; Industry: Biotechnology

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

TCON Symbol Info by TradingView

TCON by TradingView

Insider Smart

PENN NATIONAL GAMING INC (PENN) - PENN took a deep dive from $36 to $5 due to the crash, anyone who was bold enough to pick up some shares in March or April could have made a 900% profit in 2 months. But bottom fishing is always easier said than done, if one took a safer bet and followed multiple insider buying around $18, a 100% profit is still impressive.